obrixtamig + cisplatin + etoposide

Obrixtamig + cisplatin + etoposide is a combination regimen under investigation for the treatment of neuroendocrine carcinomas, including small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC-L), and extrapulmonary neuroendocrine carcinomas (epNEC). **Obrixtamig** (BI 764532, HPN328) is a bispecific antibody-based T-cell engager that bridges delta-like ligand 3 (DLL3) on tumor cells and CD3 on T-cells, prompting immune-mediated cytotoxicity against DLL3-expressing cancer cells[1][2][3]. **Cisplatin** and **etoposide** are cytotoxic chemotherapy agents: cisplatin forms DNA cross-links, leading to apoptosis, while etoposide is a topoisomerase II inhibitor, preventing DNA repair and replication. Obrixtamig is being combined with cisplatin and etoposide in clinical trials to potentially enhance antitumor activity beyond standard chemotherapy alone, particularly in patients with DLL3-positive tumors[1][2].

Other names

BI 764532BI764532BI-764532HPN328HPN-328HPN 328obrixtamig